Lack of preparation, physical health after childbirth, and early postpartum depressive symptoms.
BACKGROUND
Prior research has not examined the association of patient expectations or preparation by providers for the postpartum experience with depressive symptoms. We investigated whether lack of preparation for the postpartum experience and physical health after uncomplicated childbirth were associated with early postpartum depressive symptoms.


METHODS
We conducted a telephone survey of 720 early postpartum mothers in New York City. Mothers reported on depressive symptoms, physical symptoms, provider preparation for the postpartum experience, and other factors.


RESULTS
Nearly 39% of patients reported depressive symptoms; 24% did not feel adequately prepared by their provider for the postpartum experience. Mothers reported a range of physical symptoms: 98% reported daily vaginal bleeding, 79% reported cesarean section or episiotomy site pain, 82% reported breast pain, and 32% reported urinary incontinence. Patients who reported inadequate preparation by their provider were more likely to report depressive symptoms compared with patients who reported adequate preparation (53% vs. 35%, p < 0.001). In a multivariable model predicting postpartum depressive symptoms, adjusted odds ratios (ORs) remained elevated for perceived lack of preparation for the postpartum experience, more physical symptoms, and more physical functional limitations.


CONCLUSIONS
Further research is needed to investigate whether preparing patients for expected health consequences after pregnancy may reduce the incidence of early postpartum depressive symptoms.
Howell
Elizabeth A
EA
1 Departments of Health Evidence and Policy and Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine , New York, New York.
Mora
Pablo A
PA
Chassin
Mark R
MR
Leventhal
Howard
H
D000328:Adult; D001533:Belladonna Alkaloids / Q000627:therapeutic use; D003511:Cyclohexanols / Q000627:therapeutic use; D019052:Depression, Postpartum / Q000523:psychology*; D004338:Drug Combinations; D004879:Ergotamines / Q000627:therapeutic use; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006304:Health Status; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D008429:Maternal Welfare / Q000523:psychology; D015999:Multivariate Analysis; D009519:New York City; D010353:Patient Education as Topic; D010634:Phenobarbital / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D000069470:Venlafaxine Hydrochloride; D016387:Women's Health; D055815:Young Adult
D001533:Belladonna Alkaloids; D003511:Cyclohexanols; D004338:Drug Combinations; D004879:Ergotamines; D007529:Isoflavones; C044435:belladonna alkaloid, ergotamine, phenobarbital drug combination; D000069470:Venlafaxine Hydrochloride; D010634:Phenobarbital